Positive Phase III Results for Genentech’s Gazyva Show Superiority …
WEB5 days ago — Gazyva® (obinutuzumab) is a prescription medicine used: With the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment.
Positive phase III results for Roche’s Gazyva/Gazyvaro show
WEB5 days ago — Gazyva®/Gazyvaro® (obinutuzumab) is a Type II engineered humanised monoclonal antibody designed to attach to CD20, a protein found on certain types of B cells. 1 In lupus nephritis, disease ...
Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial
WEBSeptember 25, 2024. The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of the Phase 3 REGENCY clinical trial showing benefits of Gazyva ® (obinutuzumab) in treating people with active lupus nephritis (inflammation of the kidney associated with lupus). In development as a …
UPDATE: Positive Phase III Clinical Trial Results Announced for …
WEB5 days ago — Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an engineered humanized monoclonal antibody designed to attack CD20, a protein found on certain types of B cells that cause inflammation and damage to the kidneys. Gazyva …
Significant benefit seen with obinutuzumab in lupus nephritis trial
WEB13 hours ago — Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis. Obinutuzumab, a monoclonal antibody that targets the CD20 receptor on B-cells, is currently indicated for the treatment of chronic lymphocytic leukemia and follicular lymphoma in combination with chemotherapy under …
Genentech: Press Releases | Wednesday, Sep 25, 2024
WEBSep 25, 2024 — About Gazyva in Kidney Diseases. Gazyva ® (obinutuzumab) is a Type II engineered humanized monoclonal antibody designed to attach to CD20, a protein found on certain types of B cells. In lupus nephritis, disease-causing B cells drive persistent inflammation that damages the kidneys.
Positive Phase III results for Roche’s Gazyva/Gazyvaro in lupus
WEB1 day ago — Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. ... Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, …
Positive phase III results for Roche’s Gazyva/Gazyvaro show …
WEB5 days ago — Basel, 26 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the phase III REGENCY study of Gazyva®/Gazyvaro® (obinutuzumab) in people with active...
Roche looks to grow Gazyva's reach with phase 3 lupus nephritis win
WEB5 days ago — After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis. In a ...
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary …
WEB6 days ago — Roche RHHBY announced positive top-line data from a late-stage study of its marketed drug, Gazyva/Gazyvaro (obinutuzumab), to treat patients with active lupus nephritis (LN). The phase III REGENCY ...